Core Viewpoint - The company aims to enhance its ability to manage foreign exchange risk and mitigate the impact of significant currency fluctuations on its performance by engaging in foreign exchange hedging activities in 2026 [1] Group 1: Foreign Exchange Hedging Strategy - The company and its subsidiaries plan to continue foreign exchange hedging activities with qualified financial institutions in 2026 [1] - The hedging products will include but are not limited to forward foreign exchange contracts, foreign exchange swaps, and foreign exchange options, or combinations of these products [1] - The maximum contract value held on any trading day is expected to not exceed RMB 1 billion or its equivalent in foreign currency [1] Group 2: Authorization and Validity - The authorization for the hedging activities will be valid for a period of 12 months, from January 1, 2026, to December 31, 2026 [1] - The authorized amount can be used in a rolling manner within the specified period [1]

Core Viewpoint - BGI Genomics announced the approval of a proposal for its wholly-owned subsidiary to jointly apply for a technology project with related parties, involving a related transaction [1] Group 1 - The fourth meeting of the fourth board of directors and the seventh meeting of the fourth supervisory board were held on October 23, 2025 [1] - The proposal was approved with the related director Wang Jian abstaining from the vote [1]

Core Insights - The 2025 Global High-end Food and Quality Agricultural Products Expo (Shenzhen Food Expo) has officially opened in Shenzhen, attracting exhibitors from nearly 30 countries and regions, showcasing over 50,000 products, and aiming to create an international one-stop food industry trade platform [1][3] - A new beef quality grading group standard was released during the opening ceremony, providing a new basis for industry quality norms [1] - The expo emphasizes industry collaborative development and includes multiple strategic cooperation agreements signed during the opening ceremony [3] Group 1: Event Overview - The expo features participation from countries such as Australia, New Zealand, Canada, Uganda, Indonesia, Singapore, and Russia, along with representatives from various Chinese provinces and cities [3] - The event is organized into ten specialized exhibition areas, covering a wide range of food categories from raw materials to consumer products, promoting the integration of primary, secondary, and tertiary industries [5] Group 2: Strategic Collaborations - Partnerships were established between Sichuan Pixian Douban Co., Ltd. and China Agricultural University Shenzhen Research Institute to research salt-reduction technology for traditional foods [3] - A collaboration was signed between China Agricultural University Shenzhen Research Institute and Chongqing Hailin Pig Development Co., Ltd. to promote the "Hailing No. 1" black pig industry chain [3] - The County Economic Cooperation Alliance signed agreements to strengthen regional industrial collaboration [3] Group 3: Industry Forums and Activities - The expo hosted high-level forums, including the 2025 County Economic High-Quality Development Forum, focusing on leveraging the advantages of the Guangdong-Hong Kong-Macao Greater Bay Area [5] - The second day featured the Future Agriculture Food 500 Innovation Forum, discussing topics such as future food systems, technological changes, and investment opportunities in the agricultural sector [6] Group 4: Market Orientation - The expo emphasizes market demand orientation and enhances market-driven exhibition efforts to improve participation effectiveness [8] - Various procurement activities, including one-on-one meetings and specialized procurement sessions, were organized to facilitate supply-demand matching [8] - Major buyers such as Luckin Coffee, Nayuki Tea, Walmart, and others were invited to express procurement needs, promoting business negotiations and transactions [8]

Core Viewpoint - The rapid identification of pathogens has become a critical component of public health prevention and clinical diagnosis, prompting the company to initiate a collaborative project aimed at developing a specialized pathogen detection system [1] Group 1: Project Overview - The company’s subsidiary, Tianjin BGI Medical Testing Co., Ltd., plans to jointly apply for a national science and technology major project focused on the development of a convenient long-read sequencing system for pathogen detection [1] - The total funding for the joint application project is 120 million yuan, with 20 million yuan requested from the national budget and 100 million yuan to be self-funded by the participating institutions [1] - Among the self-funded amount, Tianjin BGI Medical Testing Co., Ltd. will contribute 50 million yuan [1] Group 2: Project Participation - Tianjin BGI Medical Testing Co., Ltd. will participate in three specific topics within the project, focusing on the development of pathogen single-molecule detection kits, supporting algorithms, databases, and research on automation applications [1]

Core Viewpoint - BGI Genomics reported a revenue of 1.042 billion yuan for Q3 2025, marking a year-on-year increase of 9.19%, while the net profit attributable to shareholders was a loss of 27.1652 million yuan, compared to a loss of 143 million yuan in the same period last year [1] Financial Performance - For the first three quarters, the company achieved a revenue of 2.674 billion yuan, reflecting a year-on-year decline of 5.39% [1] - The net profit attributable to shareholders for the first three quarters was a loss of 21.387 million yuan, compared to a loss of 124 million yuan in the same period last year [1] - The basic earnings per share for Q3 2025 was a loss of 0.0653 yuan, while for the first three quarters, it was a loss of 0.0514 yuan [1]

Core Viewpoint - BGI Genomics (300676) reported a revenue of 1.042 billion yuan in Q3 2025, marking a year-on-year increase of 9.19%, while the net profit attributable to shareholders was a loss of 27.1652 million yuan, compared to a loss of 142 million yuan in the same period last year [1] Summary by Sections Financial Performance - In Q3 2025, the company achieved a revenue of 1.042 billion yuan, reflecting a 9.19% increase year-on-year [1] - The net profit attributable to shareholders for Q3 2025 was a loss of 27.1652 million yuan, an improvement from a loss of 142 million yuan in Q3 2024 [1] - For the first three quarters of 2025, the total revenue was 2.674 billion yuan, which represents a year-on-year decline of 5.39% [1] - The net profit attributable to shareholders for the first three quarters of 2025 was a loss of 21.387 million yuan, compared to a loss of 124 million yuan in the same period last year [1]

第一条 为规范深圳华大基因股份有限公司（以下简称公司或本公司）董事、 高级管理人员的离职管理，保障公司治理稳定性及股东合法权益，根据《中华 人民共和国公司法》（以下简称《公司法》）、《上市公司章程指引》等法律、 法规、规范性文件及《深圳华大基因股份有限公司章程》（以下简称《公司章 程》）的有关规定，制定本制度。 深圳华大基因股份有限公司 董事、高级管理人员离职管理制度 深圳华大基因股份有限公司 董事、高级管理人员离职管理制度 第一章 总则 第三条 董事可以在任期届满以前提出辞任。董事辞任应向公司提交书面辞 职报告，公司收到辞职报告之日起辞任生效，公司将在两个交易日内披露有关 情况。高级管理人员辞职的，自董事会收到辞职报告时生效。 除存在本制度第七条规定情形外，出现下列规定情形的，在改选出的董事就 任前，原董事仍应当按照有关法律法规、《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作（2025 年修订）》、深圳证券交易所其 他规定和公司章程的规定继续履行职责： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员低 于法定最低人数； （二）审计委员会成员辞任导致审计委员会成员 ...

深圳华大基因股份有限公司 深圳华大基因股份有限公司 信息披露暂缓与豁免管理制度 信息披露暂缓与豁免管理制度 第一章 总则 第一条 为规范深圳华大基因股份有限公司（以下简称公司）信息披露暂缓 与豁免行为，督促公司及相关信息披露义务人（以下简称信息披露义务人）依法 合规地履行信息披露义务，保护投资者的合法权益，根据《上市公司信息披露管 理办法》《上市公司信息披露暂缓与豁免管理规定》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等法律法规、规范性文件和《深圳华大基因股份有限公司章程》（以 下简称《公司章程》）的有关规定，结合公司信息披露工作的实际情况，制定本 制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会和深圳证券交易所规定或者要求 披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实 施内幕交易、操纵市场等违法行为。 第四条 公司和其他信息披露义务人应当审慎确定信息 ...

深圳华大基因股份有限公司 关联交易管理制度 深圳华大基因股份有限公司 关联交易管理制度 第一章 总则 第一条 为规范深圳华大基因股份有限公司（以下简称公司）关联交易管理， 保障公司与关联方之间发生的关联交易能够遵循公平、公正、公开的原则，维 护公司和非关联股东的合法权益，根据《中华人民共和国公司法》《中华人民共 和国证券法》《深圳证券交易所创业板股票上市规则》（以下简称《创业板上市规 则》）《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》《深圳证券交易所上市公司自律监管指引第 7 号——交易与关联交易》等法 律、法规、规范性文件及《深圳华大基因股份有限公司章程》（以下简称《公司 章程》）的有关规定，结合公司实际情况，制定本制度。 第二条 公司在确认关联关系和处理关联交易时，应遵循并贯彻以下原则： （一）尽量避免或减少与关联人之间的关联交易； （二）确定关联交易价格时，应遵循"公平、公正、公开、等价有偿"原则， 原则上不偏离市场独立第三方的标准，对于难以比较市场价格或订价受到限制的 关联交易，应以成本加合理利润的标准确定关联交易价格； （三）关联董事和关联股东回避表决； （四）必要时 ...

深圳华大基因股份有限公司 总经理工作细则 深圳华大基因股份有限公司 总经理工作细则 第一章 总则 第一条 为进一步完善深圳华大基因股份有限公司（以下简称公司）的法人 治理结构，规范公司经理层的行为，保证总经理和其他高级管理人员依法行使职 权，根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规、规范性文件及《深圳华大基 因股份有限公司章程》（以下简称《公司章程》）等的有关规定，特制定本工作 细则。 第二条 公司依法设总经理一名。总经理主持公司日常生产经营和管理工作， 组织实施本公司董事会决议，对董事会负责。 公司根据生产经营的需要可设副总经理若干名，财务负责人一名，协助总经 理工作。 公司总经理、副总经理、财务负责人、董事会秘书及公司董事会确认的其他 高级管理人员为公司高级管理人员。 第二章 任职资格与任免程序 第三条 总经理及其他高级管理人员任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的综合 管理能力。 （二）具有知人善任调动员工积极性、建立合理的组织机构、协调各种内外 关系和统揽全局的能力。 （三）具有一 ...